RecruitingNCT07547163

Patient Voice in the Treatment of Low-grade Gliomas: Use of Patient-reported Outcomes, Vorasidenib and Radiotherapy Compared

Studying Infective dermatitis associated with HTLV-1

Last synced from ClinicalTrials.gov May 11, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Principal Investigator: Sara Morlino, MD
Fondazione IRCCS Istituto Neurologico Carlo Besta
Intervention: Vorasidenib(drug)
Enrollment: 90 target
Eligibility: 18 years · All sexes
Timeline: 2025 – 2027

Study locations (1)

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07547163 on ClinicalTrials.gov

Other trials for Infective dermatitis associated with HTLV-1

Additional recruiting or active studies for the same condition.

ENROLLING BY INVITATIONEARLY PHASE1NCT07520214
Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma
Beijing Neurosurgical Institute

See all trials for Infective dermatitis associated with HTLV-1 →

← Back to all trials